Inappropriate ADH Syndrome: Clinical Trials

41 trials for Inappropriate ADH Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

27 completed, 5 terminated, 4 unknown, 2 active not recruiting. 11 Phase 3, 9 Not applicable, 7 Phase 2, 1 Phase 1, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 311Completed 9, Terminated 2
Not applicable9Completed 4, Recruiting 2, Active not recruiting 1, Terminated 1, Withdrawn 1
Phase 27Completed 5, Terminated 2
Phase 11Completed 1
Phase 41Completed 1

Follow Inappropriate ADH Syndrome: new trials by email Literature Review of Inappropriate ADH Syndrome trials Research Report on Inappropriate ADH Syndrome

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Protein Supplementation in Hyponatremia Due to the Syndrome of Inappropriate Antidiuresis
Moltein PURE Protein Powder, Fluid restriction - Hyponatremia, Syndrome of Inappropriate Antidiuresis
Not applicableRecruitingUniversity Hospital, Basel, Switzerland702025-04-142025-07-10
Urea for Treatment of Hyponatremia in Patients With SIAD Unresponsive to Fluid Restriction
urea - SIAD - Syndrome of Inappropriate Antidiuresis
Not applicableRecruitingUniversity of Turin, Italy202024-09-122026-04-14
Low-dose Tolvaptan for Inpatient Hyponatraemia.
Tolvaptan - Hyponatremia, SIADH
UnknownKing's College Hospital NHS Trust1802024-03-152024-03-08
Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIAD
Placebo, Apelin Low Dose, Apelin High Dose - SIAD - Syndrome of Inappropriate Antidiuresis, Hyponatremia
Not applicableCompletedUniversity Hospital, Basel, Switzerland152024-03-012025-03-30
Urea for Chronic Hyponatremia
Urea - Hyponatremia, Inappropriate ADH Syndrome
Phase 2TerminatedHelbert Rondon Berrios, MD, MS22021-12-282024-05-20
Asymptomatic Bacteriuria, Hyponatremia and Geri-atric Syndrome
urine sample, Blood and urine sample - Asymptomatic Bacteriuria, Frailty
Not applicableCompletedUniversitair Ziekenhuis Brussel362021-10-302025-03-28
Effect of Protein Supplementation on Plasma Sodium Levels and Urinary Urea Excretion in Patients With SIAD
Protein supplementation, Oral urea - Syndrome of Inappropriate Antidiuresis (SIAD)
Not applicableCompletedUniversity Hospital, Basel, Switzerland182021-10-082023-02-21
Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADH
Tolvaptan (SAMSCA) - Antidiuretic Hormone, Inappropriate Secretion
Active not recruitingOtsuka Pharmaceutical Co., Ltd.3002021-03-292026-06-22
Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia
Empagliflozin 25 MG, Placebo - Hyponatremia, SIADH
Phase 4CompletedUniversity Hospital, Basel, Switzerland1132021-02-042026-09-22
Urea Therapy for Hyponatremia in Subarachnoid Hemorrhage
Urea, PLACEBO - Hyponatremia, Subarachnoid Hemorrhage
Not applicableActive not recruitingUniversity Hospital, Grenoble522020-12-032025-04-16
Changes in Serum Creatinine Levels Can Help Distinguish Hypovolemic From Euvolemic Hyponatremia
Hyponatremia, Hypovolemia
CompletedHospital San Carlos, Madrid1222019-07-302022-08-03
SOFI: A Quality Improvement Project to Standardize Use of Intravenous Fluids in Hospitalized Pediatric Patients
Education, clinical decision support tools - Intravenous Fluids, Fluid and Electrolyte Imbalance
Not applicableCompletedSeattle Children's Hospital1062019-04-012021-04-29
Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study
Empagliflozin 25mg, Placebo - SIAD - Syndrome of Inappropriate Antidiuresis, Hyponatremia
Phase 2 / Phase 3CompletedUniversity Hospital, Basel, Switzerland172017-12-152021-12-13
A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH
Tolvaptan Oral Tablet - Syndrome of Inappropriate Antidiuretic Hormone Secretion
Phase 3CompletedOtsuka Pharmaceutical Co., Ltd.162017-03-022020-11-02
Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study
Empagliflozin, Placebo - SIADH
Phase 2 / Phase 3CompletedUniversity Hospital, Basel, Switzerland882016-09-052019-06-13
Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study
Induced hypotonic hyponatremia - SIAD model, Empagliflozin 25mg Tbl, Placebo P-Tablet - Inappropriate ADH Syndrome
Phase 2 / Phase 3CompletedUniversity Hospital, Basel, Switzerland152016-03-012016-08-10
An Observational Study to Describe the Adherence to the SEOM Algorithm for the Treatment of Hyponatraemia in Spain
Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion
CompletedOtsuka Pharmaceutical Europe Ltd702015-12-012018-08-06
An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH
Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion
CompletedOtsuka Pharmaceutical Europe Ltd1002015-11-012018-03-07
An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy
Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion
CompletedOtsuka Pharmaceutical Europe Ltd692015-10-012018-04-04
Tolvaptan for Patients With Acute Neurological Injuries
Tolvaptan - Hyponatremia, SIADH
Not applicableTerminatedPolderman, Kees, H., MD, PhD252015-08-012018-09-24

Showing 20 of 41. Sign in to see all of them.

Narrower conditions

Hyponatremia (30)  ·  Diabetes Insipidus (10)  ·  Fibrosis (2)  ·  Stroke (2)  ·  Subarachnoid Hemorrhage (2)  ·  Brain Injuries, Traumatic (1)  ·  Carcinoma, Intraductal, Noninfiltrating (1)  ·  Frailty (1)  ·  Heart Failure (1)  ·  Hemorrhagic Stroke (1)  ·  Hepatitis, Infectious Canine (1)  ·  Hypovolemia (1)  ·  Ischemic Attack, Transient (1)  ·  Liver Failure (1)

Broader conditions

Brain Diseases (41)  ·  Central Nervous System Diseases (41)  ·  Endocrine System Diseases (41)  ·  Hypothalamic Diseases (41)  ·  Metabolic Diseases (41)  ·  Nervous System Diseases (41)  ·  Nutritional and Metabolic Diseases (41)  ·  Pituitary Diseases (40)  ·  Water-Electrolyte Imbalance (40)  ·  Female Urogenital Diseases (11)  ·  Female Urogenital Diseases and Pregnancy Complications (11)  ·  Kidney Diseases (11)  ·  Male Urogenital Diseases (11)  ·  Urogenital Diseases (11)  ·  Urologic Diseases (11)

Interventions

Tolvaptan (11)  ·  Urea (4)  ·  empagliflozin (4)  ·  satavaptan (4)  ·  Apelin (1)  ·  Blood Specimen Collection (1)  ·  Educational Status (1)  ·  Standard of Care (1)  ·  Tablets (1)  ·  lixivaptan (1)

Sponsors

University Hospital, Basel, Switzerland (9)  ·  Otsuka Pharmaceutical Development & Commercialization, Inc. (4)  ·  Sanofi (4)  ·  Otsuka Pharmaceutical Europe Ltd (3)  ·  CardioKine Inc. (2)  ·  Otsuka Pharmaceutical Co., Ltd. (2)  ·  European Georges Pompidou Hospital (1)  ·  Hadassah Medical Organization (1)  ·  Helbert Rondon Berrios, MD, MS (1)  ·  Hospital San Carlos, Madrid (1)  ·  Insel Gruppe AG, University Hospital Bern (1)  ·  King's College Hospital NHS Trust (1)  ·  Mario Negri Institute for Pharmacological Research (1)  ·  NYU Langone Health (1)  ·  Otsuka Frankfurt Research Institute GmbH (1)

Countries

Switzerland (11)  ·  United States (11)  ·  Germany (9)  ·  Spain (6)  ·  Belgium (5)  ·  Italy (5)  ·  France (4)  ·  Hungary (4)  ·  United Kingdom (3)  ·  Brazil (2)  ·  Canada (2)  ·  Czechia (2)  ·  Denmark (2)  ·  Hong Kong (2)  ·  Israel (2)

Top investigators

Ann Dandurand, MD (1)  ·  Beat Mueller, Prof (1)  ·  Bruno Allolio, MD (1)  ·  Frank Czerwiec, MD, PhD (1)  ·  Helbert Rondon Berrios, MD. MS (1)  ·  Isabelle Runkle, MDPhD (1)  ·  Jan Wiegand, MD (1)  ·  Jean-Philippe Bertocchio, MD, PhD (1)  ·  John K Maesaka, MD (1)  ·  Jorge G Ruiz, MD (1)  ·  Jukka Takala, MD PhD (1)  ·  Julie Refardt, MD (1)  ·  Kees Polderman, MD, PhD (1)

Results publications

PMID 17105757, PMID 22027579, PMID 25151571, PMID 20508186, PMID 20846604, PMID 21812576, PMID 23650556, PMID 24647802, PMID 25072816, PMID 25923040, PMID 30824558, PMID 33161846, PMID 33306187, PMID 34412521, PMID 34693505, PMID 34779837, PMID 36396331, PMID 37098131, PMID 42522233

NIH funding

2015 (1), 2017 (1), 2023 (1), R21DK122023 (1)